Tscan Therapeutics is trading 5.41% lower at $0.32, with no clear company-specific announcement for September 29 explaining the move. - The company’s latest major update was its September 2 restructuring, which is prior context rather than a confirmed catalyst. - Broader markets were under pressure as September 29 reports cited weak consumer confidence and declining job openings. This may add to risk-off sentiment, but market reporting does not establish a direct cause of this small-cap stock’s drop.